SymBio Pharmaceuticals

4582.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2025-12

Revenue¥1.3bn-46.7% YoY Operating income−¥4.4bn—Net income (owners)−¥4.8bn—Total assets¥3.9bn-22.2% YoY EPS (basic)¥-95.12-11.9% YoY

Full financial history and reports →

Stock price4582 · View chart ↗

Open the price chart on TradingView.

Latest filings

Fri, Sep 18 · JST1 filing

11:495% STAKESymBio Pharmaceuticals · Evo Fund + 1 joint holder · 57.40% → 56.25%−1.15pp

Wed, Sep 9 · JST1 filing

13:165% STAKESymBio Pharmaceuticals · Evo Fund + 1 joint holder · 6.44% → 57.40%+50.96pp

Mon, Sep 7 · JST1 filing

11:295% STAKESymBio Pharmaceuticals · Evo Fund + 1 joint holder · 26.61% → 6.44%−20.17pp

Tue, Aug 25 · JST1 filing

13:175% STAKESymBio Pharmaceuticals · Evo Fund + 1 joint holder · 23.82% → 26.61%+2.79pp

Wed, Aug 5 · JST1 filing

16:055% STAKESymBio Pharmaceuticals · YOSHIDA FUMINORI · 6.35%new 6.35%

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
Evo Fund	56.25%	-1.15pp	2026-09-18
Cantor Fitzgerald Europe	7.35%	-1.91pp	2026-03-04
YOSHIDA FUMINORI	6.35%	0.00pp	2026-08-05

Each holder's own ratio from its most recent large-shareholding report.